A potential new treatment for COVID-19 patients with MIS-C

Michael Walter | | Cardiovascular Business | COVID-19
Heart

Researchers believe they have identified a potential new treatment for multisystem inflammatory syndrome in children (MIS-C), detailing their findings in Critical Care Explorations.[1]

MIS-C, a new and potentially fatal condition associated with COVID-19, can cause significant damage to a patient’s heart, brain and gastrointestinal organs. Noting that the SARS-CoV-2 virus sometimes remains in the gut for weeks or even months after a COVID-19 infection, potentially triggering the development of MIS-C, specialists from Massachusetts General Hospital and Brigham and Women’s Hospital wanted to see if larazotide acetate — a medication originally developed to treat celiac disease — could provide any value as a MIS-C treatment.

Four extremely ill MIS-C patients between the ages of 3 and 17 were include in the study. Each child was given four daily doses of larazotide acetate for 21 days. An additional 22 MIS-C patients were treated with steroids and/or intravenous immunoglobulin therapy.

Overall, the four children given larazotide acetate saw their gastrointestinal symptoms decrease significantly faster than other patients. The medication was also linked to a slightly shorter hospital stay.

In addition, the team noted, inflammatory spike proteins associated with the SARS-CoV-2 virus appeared to leave the blood much faster when patients were treated with larazotide acetate.

“Our results demonstrate the urgent need for the development of diagnostic and prognostic tools to advance our understanding and treatment of this devastating disease,” lead author Lael M. Yonker, MD, pediatric pulmonologist and director of the Cystic Fibrosis Center at MassGeneral Hospital for Children, said in a prepared statement.

Related COVID-19 Cardiology Content:

Cardiac MRI sheds new light on vaccine-related myocarditis

Recovered COVID-19 patients face higher risk of heart rate abnormalities, type 2 diabetes

Children with COVID-related MIS-C fully recover within months

Cardiologists review latest data on COVID-19 vaccine-related heart damage

 

Reference:

1. Yonker, Lael M., MD, Swank, Zoe, PhD, Gilboa, Tal, PhD, et al. Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series. Critical Care Explorations: February 2022 - Volume 4 - Issue 2.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

AHA issues a scientific statement on COVID-19 cardiac arrhythmias
History of COVID-19 doubles long-term risk of heart attack, stroke or death
Monitoring acute heart patients at home linked to considerable cost savings
A key update on how COVID-19 caused dangerous MIS-C inflammation in children
Q&A: Cardiologist Karen Joynt Maddox on why new healthcare policies are not improving outcomes
COVID-19 vaccines helped heart failure patients stay out of the hospital and live longer

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."